Kong X, Lin Y, Ouyang C, Chen H, Gao X
Drug Des Devel Ther. 2025; 19:1251-1270.
PMID: 40026336
PMC: 11869757.
DOI: 10.2147/DDDT.S493011.
Kim S, Lee H, Gingras A, Ley K, Spangler J, Ginsberg M
bioRxiv. 2025; .
PMID: 39975281
PMC: 11838579.
DOI: 10.1101/2025.02.03.636356.
Alvarez F, Acuff N, La Muraglia 2nd G, Sabri N, Milla M, Mooney J
JCI Insight. 2024; 9(24).
PMID: 39704171
PMC: 11665582.
DOI: 10.1172/jci.insight.182064.
Wardell C, Boardman D, Levings M
Nat Rev Drug Discov. 2024; 24(2):93-111.
PMID: 39681737
DOI: 10.1038/s41573-024-01089-x.
Wu M, Wang Y, Wu C, Huang H, Zhou X, Wang J
Virol Sin. 2024; 39(5):821-832.
PMID: 39299564
PMC: 11738782.
DOI: 10.1016/j.virs.2024.09.007.
Acidity suppresses CD8 + T-cell function by perturbing IL-2, mTORC1, and c-Myc signaling.
Vuillefroy de Silly R, Pericou L, Seijo B, Crespo I, Irving M
EMBO J. 2024; 43(21):4922-4953.
PMID: 39284912
PMC: 11535206.
DOI: 10.1038/s44318-024-00235-w.
Signaling molecules in the microenvironment of hepatocellular carcinoma.
Chen W, Tan M, Zhang H, Gao T, Ren J, Cheng S
Funct Integr Genomics. 2024; 24(5):146.
PMID: 39207523
DOI: 10.1007/s10142-024-01427-7.
The JAK-STAT pathway: from structural biology to cytokine engineering.
Lv Y, Qi J, Babon J, Cao L, Fan G, Lang J
Signal Transduct Target Ther. 2024; 9(1):221.
PMID: 39169031
PMC: 11339341.
DOI: 10.1038/s41392-024-01934-w.
Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity.
Leonard E, Tomala J, Gould J, Leff M, Lin J, Li P
JCI Insight. 2024; 9(18).
PMID: 39115939
PMC: 11457862.
DOI: 10.1172/jci.insight.173469.
IL-2 based cancer immunotherapies: an evolving paradigm.
Rokade S, Damani A, Oft M, Emmerich J
Front Immunol. 2024; 15:1433989.
PMID: 39114660
PMC: 11303236.
DOI: 10.3389/fimmu.2024.1433989.
Causal association between skin cancer and immune cells: mendelian randomization (MR) study.
Yin W, Li R, Zhang Z, Wang Y, Tang X, Zhu L
BMC Cancer. 2024; 24(1):849.
PMID: 39020276
PMC: 11256556.
DOI: 10.1186/s12885-024-12603-0.
Cytokine/Antibody Fusion Protein Design and Evaluation.
Fabilane C, Stephenson A, Leonard E, VanDyke D, Spangler J
Curr Protoc. 2024; 4(5):e1061.
PMID: 38775006
PMC: 11115372.
DOI: 10.1002/cpz1.1061.
A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a "βγ-only" interleukin-2 variant.
Jiang Y, Chen C, Liu Y, Wang R, Feng C, Cai L
Front Immunol. 2024; 15:1369376.
PMID: 38638426
PMC: 11024467.
DOI: 10.3389/fimmu.2024.1369376.
A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.
Ptacin J, Ma L, Caffaro C, Acuff N, Germar K, Severy P
Commun Med (Lond). 2024; 4(1):58.
PMID: 38532017
PMC: 10966033.
DOI: 10.1038/s43856-024-00485-z.
Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer.
Shouse A, LaPorte K, Malek T
Immunity. 2024; 57(3):414-428.
PMID: 38479359
PMC: 11126276.
DOI: 10.1016/j.immuni.2024.02.001.
Structural insights into IL-11-mediated signalling and human IL6ST variant-associated immunodeficiency.
Gardner S, Jin Y, Fyfe P, Voisin T, Bellon J, Pohler E
Nat Commun. 2024; 15(1):2071.
PMID: 38453915
PMC: 10920896.
DOI: 10.1038/s41467-024-46235-6.
Regulatory T cells use heparanase to access IL-2 bound to extracellular matrix in inflamed tissue.
Martinez H, Koliesnik I, Kaber G, Reid J, Nagy N, Barlow G
Nat Commun. 2024; 15(1):1564.
PMID: 38378682
PMC: 10879116.
DOI: 10.1038/s41467-024-45012-9.
i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists.
Romei M, Leonard B, Katz Z, Le D, Yang Y, Day E
Nat Commun. 2024; 15(1):642.
PMID: 38245524
PMC: 10799922.
DOI: 10.1038/s41467-024-44985-x.
The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024.
Sehgal A, Tauber P, Stieger R, Kratzer B, Pickl W
Int Arch Allergy Immunol. 2023; 185(3):286-300.
PMID: 38086339
PMC: 10911178.
DOI: 10.1159/000533677.
Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.
Tomasovic L, Liu K, VanDyke D, Fabilane C, Spangler J
BioDrugs. 2023; 38(2):227-248.
PMID: 37999893
PMC: 10947368.
DOI: 10.1007/s40259-023-00635-0.